UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 28, 2008 (January 23, 2008)
ALNYLAM PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
| |
|
|
|
|
| Delaware
|
|
000-50743
|
|
77-0602661 |
|
|
|
|
|
|
| (State or Other Jurisdiction
|
|
(Commission
|
|
(IRS Employer |
| of Incorporation)
|
|
File Number)
|
|
Identification No.) |
| |
|
|
|
|
300 Third Street, Cambridge, Massachusetts
|
|
02142 |
| |
|
|
(Address of Principal Executive Offices)
|
|
(Postal Code) |
Registrant’s telephone number, including area code: (617) 551-8200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01 Other Events.
On January 23, 2008, Alnylam Pharmaceuticals, Inc. announced positive results for its ALN-RSV01
Phase II experimental infection study, referred to as the GEMINI study. The GEMINI study was
designed to evaluate the safety and anti-viral activity of ALN-RSV01, an RNAi therapeutic for the
treatment of RSV infection. Top-line results show that ALN-RSV01 was safe and well tolerated and
demonstrated statistically significant anti-viral activity. The complete results of the study will
be presented at the International Symposium on Respiratory Viral Infections meeting, to be held
February 28 — March 2, 2008 in Singapore.
The GEMINI study was a double-blind, placebo-controlled, randomized study of ALN-RSV01 or placebo
in 88 adult subjects experimentally infected with a wild type clinical strain of RSV. The study
was designed to measure the safety and anti-viral activity of ALN-RSV01, with efficacy measures
including the incidence of viral infection and the effects of treatment on the degree of viral
infection and resulting clinical symptoms. The study was performed using ALN-RSV01 or placebo
administered intranasally for five consecutive days — two days prior and three days after viral
inoculation.